MMEDF News and Press, Mind Medicine From 03/22/21

MindMed Announces Inclusion in FTSE Russell Indexes PR Newswire NEW YORK , March 22, 2021 /PRNewswire/ -- MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company announced that effective as of Friday March 19th, 2021 , M...

Numinus recently became the first Canadian public company to complete a legal harvest of Psilocybe mushrooms. The company plans to significantly expand its research facility and its revenues are growing fast thanks to the acquisition of clinics that use psychedelic therapy treatm...

Palm Beach, FL – March 19, 2021 – Psychedelic Medicines also called as hallucinogenics, are a group of substances including chemicals, such as LSD, and plants that are used in the treatment of various mental disorders such as resistant depression, panic disorder, stress and op...

MindMed Increases Cash on Hand to CAD $205.2m (USD $162m), Closes Financing of CAD $19.5m (USD $15.4m) Canada NewsWire NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO , March 9, 2021 /CNW/ ...

Palm Beach, FL – March 9, 2021 – The time of “Tune In… Turn On… and Dropout” psychedelics, such as certain, mushrooms and of course, LSD were not only not legal, but no researcher could even suggest studying the compounds… they were universal...

MindMed is targeting intriguing psychiatric issues with lucrative markets such as opioid addiction, anxiety, ADHD and cluster headaches. Recent partnerships and acquisitions seem promising and bring credible people to support the company. Accomplishing announced goals and starting...

Psychedelic medicine biotech company Mind Medicine (MindMed) Inc. (OTCQB: MMEDF)  has entered into an agreement with Canaccord Genuity Corp. to purchase for resale, on a bought deal private placement basis, an aggregate of 6,000,000 units of the Company at a price of C$3.25...

Mind Medicine (MindMed) (MMEDF) entered into an agreement with Canaccord Genuity post which the underwriter agreed to purchase for resale, on a bought deal private placement basis, 6M units at C$3.25/unit for gross proceeds of C$19.5M.It is expected that the offering will be sold to one large...

MindMed Announces C$19.5 Million Bought Deal Private Placement Offering Canada NewsWire /THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED S...

MindMed's CEO has sold almost 25% of his shares in recent months. Tabernanthalog, 18-MAC, ME-18-MC could erode 18-MC's potential. Conducting LSD-assisted psychotherapy via videoconferencing is potentially hazardous and could result in lawsuits. The underlying fundamental poten...